Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Comoros Technology Digest.
Press releases published on May 13, 2025
Advanced Technology International Acquires Carrot
GlobeNewswire
·
May 13, 2025
SUMMERVILLE, S.C., May 13, 2025 (GLOBE NEWSWIRE) -- We are excited to announce that effective March 31, 2025, Advanced Technology International (ATI), a South Carolina based 501(c)3 public service nonprofit, acquired the assets of The Common Pool, LLC, dba …
red violet to Present at the 25th Annual B. Riley Securities Investor Conference
GlobeNewswire
·
May 13, 2025
BOCA RATON, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced that it will present at the 25th Annual B. Riley Securities Investor Conference being held May 21-22 …
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
GlobeNewswire
·
May 13, 2025
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend …
Reflect Scientific Secures Patents for Data Center Cooling with Cryogenic Innovation
GlobeNewswire
·
May 13, 2025
OREM, Utah, May 13, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a leader in cryogenic technology, today announced a U.S. Patent for its innovative system to cool computer rooms using cryogenic methods. This development addresses the …
Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™
GlobeNewswire
·
May 13, 2025
The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second …
Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
GlobeNewswire
·
May 13, 2025
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …
Acronis Ecosystem Reaches 300 Technology Integrations, Drives New Opportunities for MSPs and ISVs
GlobeNewswire
·
May 13, 2025
SHAFFHAUSEN, Switzerland, May 13, 2025 (GLOBE NEWSWIRE) -- Acronis, a global leader in cybersecurity and data protection, today announces a significant milestone in the Acronis Technology Ecosystem, which now includes nearly 300 integrations, reinforcing …
CareCloud Named “Top Healthcare IT Pick for 2025” by Maxim Group; AI Initiative Recognized as Key Growth Driver
GlobeNewswire
·
May 13, 2025
SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leader in healthcare technology and generative AI solutions, today announced that Maxim Group, LLC (“Maxim Group”), a leading …
Mindera Health™ announces publication of randomized, prospective clinical utility study demonstrating improved psoriasis patient outcomes
GlobeNewswire
·
May 13, 2025
Vista, CA, May 13, 2025 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, today announced positive results from the completion of a randomized, prospective clinical trial (MATCH) aimed at demonstrating the …
Bionano Laboratories Announces Publication of the Largest Study To-Date Evaluating Clinical Utility of Optical Genome Mapping Across Multiple Hematologic Malignancies
GlobeNewswire
·
May 13, 2025
In 58% or 303 of 519 cases, optical genome mapping (OGM) revealed somatic aberrations that were not detected by the standard cytogenetic workup (SCGW), including Tier 1, Tier 2 and Tier 3 structural variants (SVs) and copy number variants (CNVs) In 15% or …
UPCX Becomes Official Associate Partner of Formula E Tokyo E-Prix 2025, Advancing Web3 and Sustainable Mobility
GlobeNewswire
·
May 13, 2025
Singapore, May 13, 2025 (GLOBE NEWSWIRE) -- UPCX, a leading blockchain-based open-source payment platform, is thrilled to announce its official sponsorship of the ABB FIA Formula E World Championship Tokyo E-Prix 2025 as an Associate Partner. This landmark …
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
GlobeNewswire
·
May 13, 2025
– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program – iTeos has initiated a …
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
GlobeNewswire
·
May 13, 2025
Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“ …
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
GlobeNewswire
·
May 13, 2025
- ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction), establishing the mechanistic …
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
GlobeNewswire
·
May 13, 2025
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, …
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements
GlobeNewswire
·
May 13, 2025
Pipeline advancements: The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review by the European Marketing Authority (EMA) and Takeda initiated its Phase 3 trial exploring mezagitamab for …
Cytokinetics Announces Positive Topline Results From MAPLE-HCM
GlobeNewswire
·
May 13, 2025
Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, …
Trace One and Connecting Food Partner to Bring Real-Time Transparency to Global Food Supply Chains
GlobeNewswire
·
May 13, 2025
PARIS, May 13, 2025 (GLOBE NEWSWIRE) -- Trace One, a premier SaaS leader in Product Lifecycle Management (PLM) and compliance software tailored to the food …
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire
·
May 13, 2025
In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene …
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
GlobeNewswire
·
May 13, 2025
- In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA - The exploratory, randomized, double-blind, placebo- …